|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZADH2 |
Gene summary for ZADH2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZADH2 | Gene ID | 284273 |
| Gene name | zinc binding alcohol dehydrogenase domain containing 2 | |
| Gene Alias | PRG-3 | |
| Cytomap | 18q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q8N4Q0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 284273 | ZADH2 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.44e-09 | 3.88e-01 | -0.1954 |
| 284273 | ZADH2 | A015-C-106 | Human | Colorectum | FAP | 9.97e-03 | -7.39e-02 | -0.0511 |
| 284273 | ZADH2 | A015-C-104 | Human | Colorectum | FAP | 1.20e-03 | -1.02e-01 | -0.1899 |
| 284273 | ZADH2 | A002-C-016 | Human | Colorectum | FAP | 7.35e-03 | -6.08e-02 | 0.0521 |
| 284273 | ZADH2 | A002-C-116 | Human | Colorectum | FAP | 1.37e-03 | -8.13e-02 | -0.0452 |
| 284273 | ZADH2 | CRC-3-11773 | Human | Colorectum | CRC | 1.70e-03 | -1.01e-01 | 0.2564 |
| 284273 | ZADH2 | C21 | Human | Oral cavity | OSCC | 4.05e-06 | 2.90e-01 | 0.2678 |
| 284273 | ZADH2 | C30 | Human | Oral cavity | OSCC | 1.73e-08 | 5.13e-01 | 0.3055 |
| 284273 | ZADH2 | C38 | Human | Oral cavity | OSCC | 3.31e-05 | 5.43e-01 | 0.172 |
| 284273 | ZADH2 | C43 | Human | Oral cavity | OSCC | 7.00e-11 | 2.31e-01 | 0.1704 |
| 284273 | ZADH2 | C46 | Human | Oral cavity | OSCC | 1.61e-06 | 2.37e-01 | 0.1673 |
| 284273 | ZADH2 | LN46 | Human | Oral cavity | OSCC | 5.10e-04 | 2.92e-01 | 0.1666 |
| 284273 | ZADH2 | SYSMH2 | Human | Oral cavity | OSCC | 6.71e-03 | 1.01e-01 | 0.2326 |
| 284273 | ZADH2 | SYSMH3 | Human | Oral cavity | OSCC | 2.52e-07 | 1.53e-01 | 0.2442 |
| 284273 | ZADH2 | SYSMH6 | Human | Oral cavity | OSCC | 3.01e-03 | 1.03e-01 | 0.1275 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006631 | Colorectum | AD | fatty acid metabolic process | 114/3918 | 390/18723 | 5.58e-05 | 9.44e-04 | 114 |
| GO:00066313 | Colorectum | FAP | fatty acid metabolic process | 81/2622 | 390/18723 | 1.43e-04 | 2.24e-03 | 81 |
| GO:00066314 | Colorectum | CRC | fatty acid metabolic process | 65/2078 | 390/18723 | 5.30e-04 | 7.42e-03 | 65 |
| GO:00454448 | Oral cavity | OSCC | fat cell differentiation | 120/7305 | 229/18723 | 2.48e-05 | 2.32e-04 | 120 |
| GO:00455983 | Oral cavity | OSCC | regulation of fat cell differentiation | 77/7305 | 139/18723 | 6.36e-05 | 5.18e-04 | 77 |
| GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
| GO:00066928 | Oral cavity | OSCC | prostanoid metabolic process | 29/7305 | 49/18723 | 3.33e-03 | 1.42e-02 | 29 |
| GO:00066938 | Oral cavity | OSCC | prostaglandin metabolic process | 29/7305 | 49/18723 | 3.33e-03 | 1.42e-02 | 29 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZADH2 | SNV | Missense_Mutation | c.847N>T | p.Pro283Ser | p.P283S | Q8N4Q0 | protein_coding | tolerated(0.09) | benign(0.035) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR | |
| ZADH2 | insertion | Frame_Shift_Ins | novel | c.430_431insTT | p.Pro144LeufsTer4 | p.P144Lfs*4 | Q8N4Q0 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| ZADH2 | insertion | Frame_Shift_Ins | novel | c.429_430insTTAATGAATAGGTCTCTCCTTCTCCTCCTCCTCCTCCTCTTCC | p.Pro144LeufsTer78 | p.P144Lfs*78 | Q8N4Q0 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| ZADH2 | insertion | Frame_Shift_Ins | novel | c.308_309insTTCATTCCTGATGCCAGATCTGATCGAGTCAGTATGTCTTCAGCTT | p.Glu103AspfsTer25 | p.E103Dfs*25 | Q8N4Q0 | protein_coding | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ZADH2 | SNV | Missense_Mutation | novel | c.1018G>C | p.Glu340Gln | p.E340Q | Q8N4Q0 | protein_coding | tolerated(0.3) | benign(0.005) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
| ZADH2 | SNV | Missense_Mutation | rs534224169 | c.845N>T | p.Ser282Leu | p.S282L | Q8N4Q0 | protein_coding | tolerated(0.22) | benign(0.02) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| ZADH2 | SNV | Missense_Mutation | rs757530499 | c.793N>T | p.Arg265Cys | p.R265C | Q8N4Q0 | protein_coding | deleterious(0.03) | possibly_damaging(0.728) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ZADH2 | SNV | Missense_Mutation | c.1009N>A | p.Leu337Met | p.L337M | Q8N4Q0 | protein_coding | tolerated(0.27) | benign(0.001) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| ZADH2 | SNV | Missense_Mutation | rs779172968 | c.478N>A | p.Ala160Thr | p.A160T | Q8N4Q0 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ZADH2 | SNV | Missense_Mutation | c.1000N>A | p.Leu334Ile | p.L334I | Q8N4Q0 | protein_coding | tolerated(0.4) | benign(0.076) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |